Nurse Anesthetist - CR in Redmond, OR Accepting Medicare

5 Nurse Anesthetist - CR nurses found. Showing 1 - 5

John Michael Unruh, CRNA Nurse Anesthetist, Certified Registered Medicare: Not Enrolled in Medicare Practice Location: 1253 Nw Canal Blvd, Redmond, OR 97756 Phone: 541-548-8131    Fax: 541-516-3877

Jeremy Thomas Johnson, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 1253 Nw Canal Blvd, Redmond, OR 97756 Phone: 541-548-8131

Rachel Lynne Mitzel, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 1253 Nw Canal Blvd, Redmond, OR 97756 Phone: 541-548-8131    Fax: 541-706-3765

Christopher A Green, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 1253 Nw Canal Blvd, Redmond, OR 97756 Phone: 541-548-8131    Fax: 541-516-3877

Olivia Boots, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 1253 Nw Canal Blvd, Redmond, OR 97756 Phone: 541-548-8131

News Archive

Researchers develop T-MOC device to study complex environment surrounding tumors

Researchers have developed a chip capable of simulating a tumor's "microenvironment" and plan to use the new system to test the effectiveness of nanoparticles and drugs that target cancer.

Columbia Laboratories amends license, supply agreement with Merck Serono for CRINONE

Columbia Laboratories, Inc. has amended its license and supply agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, for CRINONE (progesterone gel) through May 2020, representing an extension of five years beyond the current term, which was due to expire in May 2015.

Experimental drug helps patients with advanced colon cancer

According to results from a new clinical trial, an experimental cancer drug regorafenib appears to extend survival slightly in patients with metastatic colorectal cancer. Regorafenib is a so-called multikinase inhibitor, which targets several of the ways cancer develops and grows, researchers said.

FDA approves Santarus' UCERIS for induction of remission in patients with ulcerative colitis

Santarus, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis.

Read more Medical News

› Verified 9 days ago